|
Feb 21
|
Struggling bluebird bio to go private for less than $30m
|
|
Feb 21
|
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
|
|
Feb 21
|
Gene therapy maker bluebird to go private in discounted deal amid cash crunch
|
|
Feb 21
|
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
|
|
Sep 27
|
Bluebird: Q2 Earnings Snapshot
|
|
Sep 27
|
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
|
|
Sep 24
|
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
|
|
Sep 24
|
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
|
|
Sep 13
|
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
|
|
Aug 28
|
FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date
|
|
Aug 28
|
bluebird bio Announces September Investor Events
|
|
Jul 29
|
With 57% ownership of the shares, bluebird bio, Inc. (NASDAQ:BLUE) is heavily dominated by institutional owners
|
|
Jul 23
|
HHS gives thumbs down to bluebird’s fertility support programme
|
|
May 10
|
bluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ...
|
|
May 10
|
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
|
|
May 9
|
bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
|
|
May 6
|
bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
|
|
May 6
|
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
|
|
Apr 26
|
bluebird bio Announces Receipt of Expected Notice from Nasdaq
|
|
Apr 15
|
Is Bluebird Bio Stock a Buy?
|